As of 19 February 2026, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of Erlotinib, Gefitinib, and Afatinib for the treatment of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC), for government financing. The HTA Council hereby releases its preliminary recommendation on the said health technologies for stakeholder continue reading : HTA Council Preliminary Recommendation on Erlotinib, Gefitinib, and Afatinib for the Treament of Epidermal growth Factor Receptor (EGFR)-positive Non-small Cell Lung Cancer (NSCLC)